These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10944024)

  • 1. Scatter radiation from palladium-103 prostate seed implants on bone scan.
    Colomb PF; Sheehan JJ; Caride VJ
    Clin Nucl Med; 2000 Aug; 25(8):629-30. PubMed ID: 10944024
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants.
    Yue N; Chen Z; Peschel R; Dicker AP; Waterman FM; Nath R
    Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):1063-72. PubMed ID: 10571216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrepancy between clinical symptoms and Tc-99m MDP bone scan findings before and after strontium-89 therapy for metastatic bone pain of prostate carcinoma.
    Sun SS; Tsai SC; Hsieh JF; Lee JK; Kao CH
    Clin Nucl Med; 2001 Feb; 26(2):167-9. PubMed ID: 11201488
    [No Abstract]   [Full Text] [Related]  

  • 4. Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients.
    Sharkey J; Chovnick SD; Behar RJ; Perez R; Otheguy J; Solc Z; Huff W; Cantor A
    Urology; 1998 May; 51(5):796-803. PubMed ID: 9610594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetric effects of seed anisotropy and interseed attenuation for 103Pd and 125I prostate implants.
    Chibani O; Williamson JF; Todor D
    Med Phys; 2005 Aug; 32(8):2557-66. PubMed ID: 16193786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regarding Blasko et al. palladium-103 brachytherapy for prostate carcinoma. IJROBP 2000;46:839-850.
    Vikram B
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1267. PubMed ID: 11228645
    [No Abstract]   [Full Text] [Related]  

  • 7. Peripheral bone metastases in prostate cancer: a rare localization at initial presentation.
    Reigman HI; Stokkel MP
    Clin Nucl Med; 2004 May; 29(5):335-6. PubMed ID: 15069341
    [No Abstract]   [Full Text] [Related]  

  • 8. Palladium-103 brachytherapy for prostate carcinoma.
    Blasko JC; Grimm PD; Sylvester JE; Badiozamani KR; Hoak D; Cavanagh W
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):839-50. PubMed ID: 10705004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy.
    Liepe K; Kropp J; Hliscs R; Franke WG
    Clin Nucl Med; 2000 Nov; 25(11):901-4. PubMed ID: 11079588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of radioactive seed embolization to the lung following prostate brachytherapy.
    Tapen EM; Blasko JC; Grimm PD; Ragde H; Luse R; Clifford S; Sylvester J; Griffin TW
    Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):1063-7. PubMed ID: 9869230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extensive bone metastases in a patient with prostatic adenocarcinoma and normal serum prostate-specific antigen and prostatic acid phosphatase.
    Yuksel M; Cermik TF; Kaya M; Salan A; Ustun F; Salihoglu YS; Yigitbasi ON; Berkarda S
    Clin Nucl Med; 2001 Nov; 26(11):962. PubMed ID: 11595863
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma.
    Walsh P
    J Urol; 2001 Oct; 166(4):1581-2. PubMed ID: 11569476
    [No Abstract]   [Full Text] [Related]  

  • 13. Calibration, calculation, and prescription issues in permanent prostate brachytherapy with (103)Pd.
    Bice WS; Prestidge BR; Sarosdy MF
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):289-91. PubMed ID: 11163528
    [No Abstract]   [Full Text] [Related]  

  • 14. Bone metastases from poorly differentiated adenocarcinoma of the prostate diagnosed by In-111 ProstaScint (Capromab Pendetide) images with negative results of Tc-99m MDP bone scan and without significant elevation of prostate-specific antigen.
    Norris S; Halkar R; Galt J; Petros J; Keller J
    Clin Nucl Med; 1999 Nov; 24(11):905-7. PubMed ID: 10551485
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pain palliation using unsealed radionuclides].
    Kampen WU; Fischer M
    Schmerz; 2008 Dec; 22(6):699-705; quiz 706. PubMed ID: 18846393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Super bone scan: bone metastases of prostate cancer.
    Shikino K; Ikusaka M; Hirota Y; Sato E
    BMJ Case Rep; 2014 Sep; 2014():. PubMed ID: 25228679
    [No Abstract]   [Full Text] [Related]  

  • 17. Technetium-99m MDP extravasation with cutaneous pattern of ulnar innervation.
    Nguyen BD
    Clin Nucl Med; 2004 Oct; 29(10):640-1. PubMed ID: 15365440
    [No Abstract]   [Full Text] [Related]  

  • 18. Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure.
    Stock RG; Berkowitz J; Blacksburg SR; Stone NN
    BJU Int; 2012 Nov; 110(9):1257-61. PubMed ID: 22571680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of transrectal ultrasound placement of radioactive seeds for the definitive treatment of prostate cancer.
    Zachow SE; Hargis R
    J Miss State Med Assoc; 1996 Oct; 37(10):771-5. PubMed ID: 8908949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy.
    Prestidge BR; Bice WS; Kiefer EJ; Prete JJ
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1111-5. PubMed ID: 9539566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.